Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.
Search results for:

blinatumomab

blinatumomab
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Blincyto POWDER FOR INJECTION, INTRAVENOUS 35 mcg      
Comments:

Blincyto medication guide

Formulary restricted to oncologist use in the hospital outpatient in a bed status for MRD-Positive B-Cell Precursor ALL and B-Cell Precursor ALL in the Consolidation Phase.

If requested for an inpatient, submit to pharmacy administration for case by case evaluation.

Reviewed: April 28, 2015, October 2025

Blincyto 10.2025 Update.pdf

 

Last updated: Nov. 28, 2025






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2025 Rpharmy, LLC ­ All Rights Reserved